Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 68 out of 100. Prevention and risk

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

This observational study analyzed electronic health records of about 1.09 million US patients with type 2 diabetes and found that those prescribed semaglutide (a GLP-1 diabetes/weight-loss drug) were substantially less likely to receive a first-time Alzheimer's diagnosis over 3 years than those on other diabetes medications. The authors are explicit that this is a retrospective, observational analysis that cannot establish cause and effect — and a subsequent randomized trial (EVOKE/EVOKE+, listed separately) did not confirm a clinical benefit in people who already had early Alzheimer's disease.

What this study adds

Evidence grade: Preliminary

This is a follow-up (cohort) study of 1,090,000 participants. In this observational analysis of health records, people with type 2 diabetes prescribed semaglutide were less likely to receive a first-time Alzheimer's diagnosis over 3 years than those on other diabetes drugs. Reported effect size: HR 0.33 (95% CI 0.21-0.51) vs. insulin; HR 0.59 (95% CI 0.37-0.95) vs. other GLP-1 agonists.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Wang, W., Wang, Q. Q., Qi, X., Gurney, M., Perry, G., Volkow, N. D., et al. (2024). Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US. Alzheimer's & Dementia.

Vancouver

Wang W, Wang QQ, Qi X, Gurney M, Perry G, Volkow ND, et al. Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US. Alzheimer's & Dementia. 2024.

BibTeX

@article{wang2024-228e687c,
  author  = {Wang, W. and Wang, Q. Q. and Qi, X. and Gurney, M. and Perry, G. and Volkow, N. D. and Davis, P. B. and Kaelber, D. C. and Xu, R.},
  title   = {{Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US}},
  journal = {Alzheimer's \& Dementia},
  year    = {2024}
}

Built from the record alzhub holds for this paper, not looked up. This record has no DOI, so the citation leaves it out. Volume, issue and page numbers are not held in the record. The record names 9 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.

Key findings

Why it matters

In this observational analysis of health records, people with type 2 diabetes prescribed semaglutide were less likely to receive a first-time Alzheimer's diagnosis over 3 years than those on other diabetes drugs. The authors state this cannot establish cause and effect, and a later randomized trial did not confirm a clinical benefit in people who already had early Alzheimer's disease.

Study details

Limitations

Observational/retrospective design precludes causal inference; only 3 years of follow-up; possible diagnostic misclassification; no medication-adherence data; a subsequent RCT (EVOKE/EVOKE+) found no benefit once Alzheimer's was already symptomatic.

How this study scored 68/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record left out, no data; Study design 7 of 12; Strength of evidence 2 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 4 of 4; Effect reported 3 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited left out, no data; Citations per year left out, no data; Impact for its field and year left out, no data; Cited by studies here 0 of 6; Still being cited left out, no data; Senior author's track record left out, no data; Institution's track record left out, no data; Multicenter collaboration left out, no data; Indexed in PubMed 0 of 2; Free to read left out, no data. 42 of the 62 points it could be judged on, which is 68 of 100. Total 68 of 100.42 of the 62 points we could judge = 68 of 100

Published in a leading specialty journal, and it is a cohort study following people over time. Scored zero for randomized / blinded and indexed in PubMed because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, still being cited, senior author's track record, institution's track record, multicenter collaboration and free to read, so those were left out: it earned 42 of the 62 points we could judge it on, which is 68 out of 100.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (Alzheimer's & Dementia)
Journal's citation record — / 4 No journal record from OpenAlex — left out of this score
Study design 7 / 12 A cohort study following people over time
Strength of evidence 2 / 5 Rated “preliminary” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2024 — within 3 year(s) of the newest study here
Sample size 4 / 4 1,090,000 participants
Effect reported 3 / 3 Effect reported with a statistic (interval, p-value, ratio or similar)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited — / 7 No citation count (not found in OpenAlex) — left out of this score
Citations per year — / 5 No citation count or no year — left out of this score
Impact for its field and year — / 6 No field-weighted citation impact (OpenAlex has none yet) — left out of this score
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited — / 4 No yearly citation counts — left out of this score
Senior author's track record — / 4 Senior author's record not available — left out of this score
Institution's track record — / 3 No institution listed in OpenAlex — left out of this score
Multicenter collaboration — / 3 Institutions not listed — left out of this score
Indexed in PubMed 0 / 2 No PubMed ID and no DOI — scores zero (not stated in the record — scored 0)
Free to read — / 2 Access not recorded — left out of this score
Points 42 / 62 Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 42 of the 62 points we could judge it on is 68 out of 100.
Total 68 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.

Studies in the library that share something with this one. The line above each title says what.

Related studies in Prevention and risk from nearby years

Also tagged “trial”

783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Prevention and risk

See all studies in Prevention and risk →